Transforming Cancer Care Through Data

COTA provides oncology research and development, regulatory, commercial, and HEOR teams with detailed real-world patient data to discover new treatment protocols and transform cancer care.


Powering the Next Generation of Cancer Research

Real, longitudinal patient data across dozens of patient subgroups and oncology disease areas help pharmaceutical and biotech companies optimize their research, development, and commercialization strategies.


For Research and Development Teams

COTA's curated database of oncology patient data allows drug development teams to expedite timelines by giving them the tools to generate and test hypotheses and identify subpopulations of interest, identify predictors of treatment response and inform go/no-go research decisions.
Learn More

For Regulatory Teams

Use COTA data to support regulatory submissions and augment clinical trials with cohorts of patients from real-world settings, supplement clinical trial data with real-world benchmarks, and provide external validity of data collected in single-arm studies.
Learn More

For Commercial Teams

Post approval, COTA data can help validate commercial strategy hypotheses, support label expansion studies/life cycle management/patent considerations, and conduct Phase IV studies.
Learn More

For HEOR Teams

Utilize COTA data to carry out essential post-marketing studies that validate safety and patient outcomes, respond to inquiries from health authorities and payers, and support new dosing schedules, routes of administration, among other requirements.
Learn More

For Cancer Centers and Oncologists

COTA’s data curation service and oncology analytics solution help oncology practices and cancer centers make sense of fragmented and often incomplete EHR data.
Learn More

Trusted by top biopharma and providers:

The Highest-Quality Cancer RWD and Insights at Your Fingertips

COTA data includes over 2M+ patients across a variety of cancer diagnoses, treatment settings, and demographics and is regularly maintained and updated to ensure quality, accuracy, relevance, and linkability.


How COTA Partners with Life Sciences Teams

Curated Real-World Datasets

Get access to a massive database of longitudinal real-world outcomes datasets curated to specific cancer types, subpopulations, or broad population research.

Real-World Insights and Support

Get expert clinical insights, study design support, and statistical analysis.

What Our Clients are Saying

We are using more data from COTA in our control arm than any other RWD provider
Senior Executive
Top 5 Pharma Company
We utilized COTA's RWD platform to uncover insights about real-world treatment patterns and outcomes across their multiple myeloma patient population
Dr. Harsh Parmar
Oncologist at Hackensack Meridian Health

We are using more data from COTA in our control arm than any other RWD provider

Senior Executive

Top 5 Pharma Company


Powering the Next Generation of Cancer Research

Explore our collection of clinical research, recent press, podcasts, and more.

RWD and GenAI: How technology’s new power couple will revolutionize life sciences

Generative AI (GenAI) is quickly proving itself to be one of the most transformative technologies of our time with its ability to synthesize data and create new content as well as (or…

COTA and Texas Oncology Collaborate to Advance AI-Enabled Precision Medicine

New York — COTA, Inc., in collaboration with Texas Oncology’s Precision Health Informatics, LLC (PHI), announces an innovative collaboration aimed at revolutionizing precision medicine across Texas Oncology’s community cancer centers. Leveraging COTA’s AI-powered…

Who, what, when…and especially where: Why care settings matter for representative real-world datasets

A vast majority of cancer patients’ care starts with a visit to a primary care provider for a routine screening or consult for a worrisome symptom.  They may visit a local hospital…


Bring Clarity to Your Cancer Research

Partner with COTA for the highest-quality curated cancer patient datasets.